AI-generated · cited to primary sources · not investment advice
Laurus Labs (540222) Apr 2025 Filing Analysis
How durable is the business?
Generic Finished Dosage Forms (FDF) showed steady growth, supported by new product launches in the US and expansion of manufacturing lines. (2 expanding)
“FDF: 1,582 [FY25] vs 1,414 [FY24] 12%... Recent US launches picking up pace following new contracting”
The share of revenue from Anti-Retroviral (ARV) products, which are primarily sold as APIs and formulations, has significantly decreased over the last five years as the company diversifies into other therapeutic areas. (1 shifted, 4 expanding)
“Today, our share of ARV revenues have come down from 67% to 45% in the last five years”
The company maintained its strong regulatory moat, completing 160 audits in 2025 (a 20% increase) with no critical findings and receiving an EIR for Unit 4. (5 stable)
“In 2025, the company underwent close to 160 quality audits... which was over 20% more than the previous year. Company has successfully completed audits without any critical findings.”
The Generic API segment is contracting as the company prioritizes capacity for higher-margin CDMO opportunities and faces price erosion in the market. (1 contracting)
“API: 2,438 [FY25] vs 2,545 [FY24] -4%... soft FY delivery driven by prioritise API capacity allocation into attractive business opportunities + price erosion”
See the full cited Business Model analysis of Laurus Labs
Where does growth come from?
The Generics division is showing a steady recovery, particularly in the final quarter of FY25, though full-year growth was a modest 2% due to API pricing pressure. (1 steady across 1 signal)
“GENERICS – Impacted by soft API business... Continued strong Q/Q growth ARV & DM led.”
See the full cited Future Growth analysis of Laurus Labs
What could break the thesis?
EASING. The company has successfully diversified its revenue mix. ARV revenue share has declined from 67% in FY19 to 46% in FY25, while the CDMO share has more than doubled to 28%. (1 easing)
“ARV revenue share declining & CDMO share more than doubled... ARV share 46% (FY25) vs 67% (FY19)”
Trajectory is EASING. ARV revenue share has dropped from 67% to 45% over the last five years as the company successfully diversifies into CDMO (now 28%) and other generic therapeutic areas. (5 easing)
“Today, our share of ARV revenues have come down from 67% to 45% in the last five years, whereas our CDMO share has moved from 13% to 28%”
See the full cited Risk analysis of Laurus Labs
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.